Considering the contradictory findings of previous studies and suggested stage-dependent associations, it is crucial to deeply investigate the possible longitudinal associations between TREM2-related microglia activation and AD pathological hallmarks to identify new therapeutic targets. This evidence concerns the gene TREM2 and Alzheimer disease.